Larimar Therapeutics Inc
NASDAQ:LRMR

Watchlist Manager
Larimar Therapeutics Inc Logo
Larimar Therapeutics Inc
NASDAQ:LRMR
Watchlist
Price: 3.81 USD -2.56% Market Closed
Market Cap: 326.1m USD
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of LRMR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LRMR Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-4
Industry
23.7
Forward
-1.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-4.8
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-4.7
Industry
24.3
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
31
vs Industry
65
Median 3Y
1.9
Median 5Y
2
Industry
3.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
20
Median 3Y
-1.7
Median 5Y
-1.7
Industry
6.1
Forward
-1.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
18
Median 3Y
-1.7
Median 5Y
-1.7
Industry
6.5
Forward
-1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
21
Median 3Y
-2.2
Median 5Y
-2
Industry
7.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
17
Median 3Y
-2.2
Median 5Y
-2
Industry
6.3
More Details
184.9
EV/IC
EV/IC
Enterprise Value to IC
184.9
vs History
3
vs Industry
14
Median 3Y
13.1
Median 5Y
12.8
Industry
5.7
More Details

Multiples Across Competitors

LRMR Competitors Multiples
Larimar Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Larimar Therapeutics Inc
NASDAQ:LRMR
326.1m USD 0 -2.5 -1.1 -1.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 790 068.7 -160 599.2 -195 018.6 -192 793.3
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.9 -532 -579.3 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD 16.5 1 216.4 164 198.9
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.5 57.8 59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average P/S: 3 379 222
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 790 068.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 084.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.5
46%
0.4
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average P/E: 191.7
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 599.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 216.4
N/A N/A
NL
argenx SE
XBRU:ARGX
33.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average EV/EBITDA: 40.2
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 018.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164
N/A N/A
NL
argenx SE
XBRU:ARGX
57.8
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Larimar Therapeutics Inc
NASDAQ:LRMR
Average EV/EBIT: 46.4
Negative Multiple: -1.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59.4
N/A N/A

See Also

Summary
LRMR intrinsic value, competitors valuation, and company profile.
DCF Valuation
LRMR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LRMR stock valuation using valuation multiples.
Wall Street Estimates
LRMR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LRMR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.